JPMorgan Chase & Co. Trims Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

JPMorgan Chase & Co. trimmed its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 928,589 shares of the company’s stock after selling 78,930 shares during the quarter. JPMorgan Chase & Co. owned 1.31% of Ventyx Biosciences worth $2,034,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. American Century Companies Inc. lifted its stake in Ventyx Biosciences by 12.4% in the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company’s stock worth $147,000 after acquiring an additional 7,414 shares during the period. State Street Corp lifted its position in shares of Ventyx Biosciences by 0.8% in the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after purchasing an additional 9,783 shares during the period. Catalina Capital Group LLC bought a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $25,000. Palumbo Wealth Management LLC increased its holdings in Ventyx Biosciences by 97.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock valued at $52,000 after buying an additional 11,792 shares during the period. Finally, AXQ Capital LP bought a new position in Ventyx Biosciences in the fourth quarter worth approximately $29,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Up 8.6 %

NASDAQ VTYX opened at $1.26 on Friday. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $5.66. The company has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.87. The firm has a market cap of $89.62 million, a PE ratio of -0.53 and a beta of 0.75.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.13. On average, equities research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.